查詢結果分析
相關文獻
- 抗精神病藥物新選擇用藥--Lurasidone
- 結核病與思覺失調症
- Improvement of Tardive Dyskinesia and Tardive Dystonia in a Schizophrenic Female Patient Using a Low-dose Aripiprazole
- Refeeding Syndrome in Schizophrenia
- Renaming Schizophrenia in Far East Asian Countries
- 思覺失調症病患之主要照顧者復原力與健康狀態之探討
- Anemia Secondary to Valproic Acid in a Female Patient with Schizoaffective Disorder
- 體感式電玩介入對慢性思覺失調症病人健康體適能之成效
- 雙極性疾患與思覺失調症照顧負擔之比較研究
- 「思覺失調症醫療給付改善方案」成效探討--以臺灣北部某精神專科醫院為例
頁籤選單縮合
題名 | 抗精神病藥物新選擇用藥--Lurasidone=The New Choice of Antipsychotic Drugs: Lurasidone |
---|---|
作者姓名(中文) | 鄭淑文; 林昱誠; 鄭榆柔; | 書刊名 | 藥學雜誌 |
卷期 | 34:3=136 2018.09[民107.09] |
頁次 | 頁67-72 |
分類號 | 418.21 |
關鍵詞 | 思覺失調症; 雙極性疾患之鬱症; Schizophrenia; Bipolar I depression; Lurasidone; |
語文 | 中文(Chinese) |
中文摘要 | Lurasidone 為非典型抗精神病藥物,於2011年在美國上市,現今已核准的適應症包 括思覺失調症 (schizophrenia) 及第一型雙極性疾患之鬱症 (bipolar I depression)。其療效 可能是經由結合中樞多巴胺第二型 (D2)、血清素第二型 (5-HT2A) 及七型 (5-HT7) 受體 拮抗作用所調控。用於思覺失調症建議劑量為40-80 mg/day,用於第一型雙極性疾患之 鬱症建議劑量為20-120 mg/day。飯後30分鐘內或隨餐服用 (至少350大卡),可達最佳治 療效果。此外,使用 lurasidone 治療,產生鎮靜或體重增加/肥胖的風險相對較低。 |
英文摘要 | Lurasidone is a novel atypical antipsychotic drug that was recently approved for the treatment of schizophrenia and bipolar depression by the the Food and Drug Administration of United States. Based on its pharmacodynamics profile, it is believed that the drug’s clinical action is mediated mainly through the D2, 5-HT2A and 5-HT7 receptors inhibition. In patients with schizophrenia the recommended dose range is 40-80 mg/day. In bipolar depression broader dosage ranges (20-120 mg/day) were found to be effective. Lurasidone should be administered with food at least 350 kcal-to ensure maximum exposure. On the other hand, treatment with lurasidone yields relatively lower risk for developing sedation or overweight/obesity. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。